CJC-1295 vs Pramlintide

CJC-1295 binds to and activates pituitary GHRH receptors, stimulating pulsatile GH secretion. The DAC modification enables covalent binding to albumin, dramatically extending the active peptide half-life. This sustained GH pulse pattern is intended to mimic physiological GH release more closely than shorter-acting GHRH analogues.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). The DAC (Drug Affinity Complex) form binds to albumin in the bloodstream, extending its half-life to several days and enabling sustained elevation of GH and IGF-1 levels. It is commonly researched alongside GHRP peptides for body composition and recovery outcomes.

Synthetic amylin analogue; activates amylin receptors in hypothalamus; slows gastric emptying, suppresses glucagon, enhances satiety

FDA-approved synthetic amylin analogue that complements insulin therapy. Reduces postprandial glucose spikes and suppresses appetite, aiding weight management in T1D and T2D.